Octopus: Progressive MS trial (playlist)

Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS), which is designed and run by the MRC CTU at UCL. Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recruiting participants for the next few years.  

The podcast mini-series will explore the trial from different perspectives by talking to neurologists, MS experts and people affected by MS.  

Part 1 covers the treatment and research landscape of MS and the challenges of treating progressive MS. It features Jeremy Chataway, neurologist at the National Hospital for Neurology and Neurosurgery at UCLH, Professor of Neurology at UCL and co-lead of the Neurodegenerative Diseases progamme at the MRC CTU at UCL, who is leading the Octopus trial. We also hear from Dawn Lyle, Lead Research MS Nurse, and Matthew Justin, MS Specialist, who are based at the Anne Rowling Regenerative Neurologic Clinic in Edinburgh.  
-
For more information and to access the transcript: https://bit.ly/3S6FKP4

For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk

As a listener, your opinion is very valuable to us. Please help us to improve the podcast in the future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

Octopus (part 1): The MS landscape with Jeremy Chataway, Dawn Lyle and Matthew Justin

Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS), which is designed and run by the MRC Clinical Trials Unit at UCL. Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recruiting participants for the next few years.  

The podcast mini-series will explore the trial from different perspectives by talking to neurologists, MS experts and people affected by MS. 

Part 2 of the series explores our Octopus trial in depth. Professor Jeremy Chataway, lead investigator of Octopus, discusses its novel design, the treatments it will test, and the criteria for people to take part. He also explains the data researchers will collect and analyse to find out if a treatment is working.
-
For more information and to access the transcript: bit.ly/3S6FKP4 

For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk 

As a listener, your opinion is very valuable to us. Please help us to improve the podcast in the future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

Octopus (part 2): Introducing the trial with Jeremy Chataway

Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS), which is designed and run by the MRC Clinical Trials Unit at UCL. Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recruiting participants for the next few years.  

The podcast mini-series will explore the trial from different perspectives by talking to neurologists, MS experts and people affected by MS. 

In Part 3, MS experts Dawn Lyle and Matthew Justin walk us through the journey that trial participants take when taking part in Octopus, from how to register your interest in the trial, to what to expect on your first visit.
-
For more information and to access the transcript: bit.ly/3S6FKP4

For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk

As a listener, your opinion is very valuable to us. Please help us to improve the podcast in the future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

Octopus (part 3): The patients’ experience with Dawn Lyle and Matthew Justin

Octopus is a new clinical trial for people living with progressive multiple sclerosis (MS), which is designed and run by the MRC Clinical Trials Unit at UCL. Thanks to its multi-arm multi-stage platform design, Octopus has the potential to transform the way treatments for progressive MS are tested. The trial is now open in the UK and will be recruiting participants for the next few years.  

The podcast mini-series will explore the trial from different perspectives by talking to neurologists, MS experts and people affected by MS.  

In the final part, we explore the role of people affected by MS in the Octopus trial. Susan Scott, a pharmaceutical publications specialist and Octopus patient representative, shares her involvement in the trial and explains how PPI has benefited Octopus so far.

-
For more information and to access the transcript: bit.ly/3S6FKP4

For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk

As a listener, your opinion is very valuable to us. Please help us to improve the podcast in the future by filling in this short survey: forms.office.com/e/PjfjQ5Mn6g

Octopus (part 4): Involvement of people affected by MS with Susan Scott

The Trial Talk podcast explores how our work at the MRC Clinical Trials Unit at UCL is improving health in the UK and worldwide. In this series, we hear from world-leading experts about the studies we carry out. We delve into trials on cancer, infections and neurodegenerative diseases, explore how public and patient involvement shapes our work, and discover new ways to run smarter studies.

Octopus (part 3): The patients’ experience with Dawn Lyle and Matthew Justin

MRC CTU at UCL - Trial Talk podcast